GWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients

Authors

  • Troels K. Bergmann School of Pharmacy, University of Queensland, Brisbane, Australia; Clinical Pharmacology, Institute of Public Health, University of Southern Denmark, Odense, Denmark
  • Werner Vach Clinical Epidemiology, Institute of Medical Biometry and Medical Informatics, University Medical Center, Freiburg, Germany
  • Søren Feddersen Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark
  • Lise Eckhoff Department of Oncology, Odense University Hospital, Odense, Denmark
  • Henrik Gréen Clinical Pharmacology, Department of Medical and Health Sciences, Linköping University, Linköping, Sweden; Science for Life Laboratory, School of Biotechnology, Division of Gene Technology, Royal Institute of Technology, Solna, Sweden
  • Jørn Herrstedt Department of Oncology, Odense University Hospital, Odense, Denmark
  • Kim Brosen Clinical Pharmacology, Institute of Public Health, University of Southern Denmark, Odense, Denmark

DOI:

https://doi.org/10.3109/0284186X.2012.707787

Abstract

No abstract available

Downloads

Download data is not yet available.

Downloads

Published

2013-05-01

How to Cite

Bergmann, T. K., Vach, W., Feddersen, S., Eckhoff, L., Gréen, H., Herrstedt, J., & Brosen, K. (2013). GWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients. Acta Oncologica, 52(4), 871–873. https://doi.org/10.3109/0284186X.2012.707787

Issue

Vol. 52 No. 4 (2013): Acta Oncologica

Section

Articles